What is the price of Halozyme Therapeutics (HALO) today?

The current price of Halozyme Therapeutics (HALO) is $ 66.98, representing a 16.07% gain over the past year. The stock began the year trading around $ 67.30 and is currently priced at $ 66.98. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Halozyme Therapeutics (HALO) pay dividends?

Halozyme Therapeutics (HALO) did not pay dividends over the past year.

Is Halozyme Therapeutics (HALO) a good investment?

Halozyme Therapeutics (HALO) is currently trading at $ 66.98 with a P/E ratio of 24.01%. This represents a 2,332% premium compared to its historical average P/E. Over the past year, the stock has gained 16.07 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 16.07%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Halozyme Therapeutics (HALO) stock?

You can buy Halozyme Therapeutics (HALO) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol HALO and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Halozyme Therapeutics (HALO) yield today?

Over the past month, Halozyme Therapeutics (HALO) has returned 0.74% — 16.07% over the past year, and 55.94% over the past five years, including price appreciation and dividends.In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.If you were to purchase 100 shares of Halozyme Therapeutics (HALO) today at the current price of $ 66.98 your total investment would be $ 6,697.50.Based on historical performance, the investment would have grown to approximately:$ 7,773.79 after 1 year$ 10,444.08 after 5 years$ 38,143.60 after 10 yearsPast performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

Halozyme Therapeutics (HALO): Stock Price, Earnings & Key Metrics

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	21.84	7.39	33.81%	2.14%	$ 585.48 B	28.46%
PFE	20.72	1.73	8.35%	6.07%	$ 161.03 B	12.42%
ABBV	87.32	0.00	0.00%	3.18%	$ 369.02 B	6.91%
NVO	10.48	5.40	51.50%	4.56%	$ 164.23 B	33.05%
MRK	16.43	0.00	0.00%	2.71%	$ 300.00 B	28.08%
AZN	30.87	6.48	20.99%	1.57%	$ 315.61 B	17.41%
GILD	20.39	7.67	37.62%	2.28%	$ 173.52 B	28.90%
BMY	17.20	-3.56	-20.72%	4.18%	$ 121.35 B	14.64%
ZTS	19.33	15.51	80.25%	1.72%	$ 51.66 B	28.23%
REGN	17.42	2.51	14.41%	0.47%	$ 78.47 B	31.41%
AMGN	24.32	21.66	89.06%	2.78%	$ 187.54 B	20.98%
MCK	24.84	-1,089.08	-4,383.84%	0.36%	$ 107.82 B	1.09%
VRTX	28.19	5.97	21.18%	0.00%	$ 111.43 B	32.94%
CAH	30.39	-18.71	-61.56%	0.95%	$ 50.52 B	0.68%
ADMA	14.89	4.58	30.78%	0.00%	$ 2.19 B	28.80%
BIIB	20.16	1.43	7.08%	0.00%	$ 26.07 B	13.07%
HRMY	9.96	1.82	18.24%	0.00%	$ 1.58 B	18.27%

Halozyme Therapeutics, Inc. is a biotechnology company operating in the healthcare sector, focused on developing drug delivery technologies that improve the administration of biologic therapies.

Its core activities include:

• Development of drug delivery technologies for biologic therapies.
• Licensing of proprietary biotechnology platforms.
• Strategic partnerships with pharmaceutical and biotechnology companies.
• Research and development of innovative subcutaneous drug delivery solutions.

The company’s main innovation is the Enhanze platform, which is based on a recombinant human hyaluronidase enzyme designed to enhance the absorption and dispersion of injected drugs in subcutaneous tissue. This technology allows certain biologic therapies that traditionally require intravenous infusion to be administered more quickly through subcutaneous injection.

Company performance is influenced by the adoption of its drug delivery platform by pharmaceutical partners, regulatory approvals for partnered therapies, research and development progress, and broader trends in the biopharmaceutical industry.

Halozyme Therapeutics, Inc. shares trade on the Nasdaq under the ticker HALO.

History and Development

Halozyme was founded in 1998 in San Diego, California, with the objective of developing technologies that improve the delivery of injectable biologic medicines.

In its early years, the company focused on research and development of the Enhanze platform while establishing strategic collaborations with pharmaceutical partners.

The company completed its initial public offering (IPO) on the Nasdaq in 2004, raising capital to support further research, technology development, and partnership expansion.

Over time, Halozyme expanded the number of pharmaceutical companies using its platform, strengthening its licensing and royalty-based business model while broadening the applications of its drug delivery technology.

HALO

Halozyme Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment HALO

review the fundamentals of Halozyme Therapeutics shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Halozyme Therapeutics

Halozyme Therapeutics Inc.

United States

28 years

2004

132

History and Development

Additional Information

PROFIT X PRICE HALO

Financial Results HALO

HALO cash flow

Asset, Revenue and Profit Growth - HALO

HALO balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca